Issue link: http://osercommunicationsgroup.uberflip.com/i/709458
C h a i n D r u g s t o r e D a i l y Tu e s d a y, A u g u s t 9 , 2 0 1 6 8 4 technicians – the most robust list in the industry. It can guide you to maximize exposure of your communication with a dynamic subject line, headline, preheader (preview text), email content and layout. Pharmacists and technicians approach their email as we do. We glance at our inbox and delete emails that do not seem relevant or useful, respond to those that are more time sensitive, and flag others to review at a later time. Therefore, your communication must capture the recipi- ent's attention within just a few seconds. The first step of a successful campaign is to ensure the email message hits the inbox and not a junk folder. Its 25-plus servers are dedicated to PDQ emails and are not shared servers. In addition, it uses unique IP addresses for all PDQ emails to ensure your message will arrive in the recipient's inbox. Viewability is the second step. By utilizing responsive design HTML, your email will format according to the device used by the recipient such as a computer, P D Q C o mmunicatio ns (C o nt'd. fro m p. 1 ) tablet or mobile device. It then tests your HTML artwork to see how the message will render on different platforms and guide you to fix any rendering issues before your actual deployment. PDQ can ramp up your ROI with high open and click-through rates. By adding an echo email to your program, you can increase your analytics without bombard- ing the recipient. After an email is deployed, for only 50 percent of the cost, it re-deploys, or echoes the same email to the target list, while suppressing openers of the original email. The email plus echo pro- grams have proven successful with open rates averaging 25 percent, significantly higher than the competition. It is so confi- dent in its electronic programs that it guar- antees at least a 10 percent gross open rate or it will re-deploy for free. Let PDQ be your digital communi- cations partner. It can generate the aware- ness levels you may be missing. Visit PDQ Communications at booth #2157. "We are continuously doing market research and expanding our product lines to our existing and new customers. We pride ourselves in delivering top quality bandages, surgical tape, heat patches, first aid kits and more – with a promise to our customers that we strive for nothing but the best manufacturing practices," says Jennie Lim, Sales Manager. MCURE's U.S. office is located in City of Industry, California, and the com- pany's state-of-the-art manufacturing facilities are located in Suzhou, Nanjing and Shanghai. Top quality, competitive pricing, excellent service and dedication are the key elements that bring MCURE Health Solutions, Inc. to its success in the industry. With more than 15 solid years of manufacturing experience, MCURE's mission is to deliver the highest quality MCURE Health Solutions (Cont'd. from p. 1 ) health products with the most cost-effec- tive production packages to its customers. With an international presence, MCURE offers the advantages of com- petitive pricing, customer convenience, high-quality products and the capabilities to deliver complete customer satisfaction. "Our company's vision focuses on the idea of sharing. We are not just a manufacturing facility; we also invest our financial resources into research and development to bring innovations to our next generation of more sophisticated health care products," Lim says. "Our facilities have consistently received high marks at FDA site reviews, which reflect our dedication and commitment to prod- uct excellence." Visit MCURE Health Solutions, Inc. at booth #1964. For more information, call 626.839.9001 or go to www.m-cure.net. is a global generic pharmaceuticals manu- facturer. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure and strategic expansion opportunities – all con- tributing to its significant growth. The com- pany prides itself on its unwavering com- mitment to quality, strong business rela- tionships and innovative approach to maxi- mizing value. Amneal, which is privately- held, collaborates directly with whole- salers, distributors, retail chains, hospitals, mail order companies and Group Purchasing Organizations. It follows the thought that the world "is our family," which means it not only cares about its direct customers, the pharmaceutical indus- try, it cares for its customers' ultimate cus- tomer: the patient. This commitment to delivering value through the entire length of the customer chain is rooted in Amneal's core principles: high-touch customer serv- ice, transparency, integrity and quality. A strong belief in developing meaningful business relationships rather than transac- tional ones extends from the company's top management through the individuals who pick, pack and ship product. "The company's success is enabled by our sharp focus on growth strategy along with significant investments in R&D and infrastructure," explains Jim Luce, Amneal Executive Vice President, Sales and Marketing. Amneal is highly-focused on driving mutual value creation with customers and business partners by going beyond provid- ing superb quality products across all dosage forms. Amneal's superb R&D, effi- cient and effective production, strategic sourcing and fine-tuned sales operations/logistics complete the cycle. A mneal (C o nt'd. fro m p. 1 ) From the start, Amneal has reinvested heav- ily, with a disproportionate percentage of its revenue, in growing and broadening its product portfolio across all dosage forms and therapeutic categories. Simultaneously, it continues to expand and enhance infra- structure in order to comfortably service future growth, thus ensuring the capacity to meet anticipated product approvals. The company anticipates launching more than 40 products this year, including some exciting first-to-file and first-to-mar- ket products as well as new dosage-forms and greatly expanding its women's health product line. Luce adds, "From the early days of the company, there's been an unrelenting com- mitment to quality, both measurably by FDA criteria and attitudinally throughout our organization. Since the beginning, we've had 45 inspections without any significant 483s across our nine FDA-approved facili- ties. This commitment to quality stems from our guiding principle to view the consumer of our products like a family member. Would you give your family anything but the very best? This belief permeates throughout the organization, instilling great confidence among our customers and our mutual cus- tomer, the patient." What is clear is that there isn't any individual part of Amneal that drives the company's value. What drives that value is the belief that it is a team – the scientists, engineers, operations, sales – that creates the most value for customers. Luce concludes, "We believe by focusing on our customers and patients, and standing by the values of quality and integrity, this path will allow us to continue sustaining our growth for years to come." Visit Amneal at booth #308. For more information, go to www.amneal.com. KH: TAGI Pharma, Inc. is a specialty pharmaceutical company and subsidiary of Precision Dose, Inc. With a robust pipeline and product mix, TAGI Pharma is providing market opportunities in both retail and institutional segments. TAGI's portfolio maintains product emphasis on tablets and capsules, while encompassing liquids, powders, creams and ointments. We are constantly seeking new partners and products, driving rapid and continu- ous growth of our portfolio. CDD: What differentiates TAGI Pharma? KH: Our people and how we approach the market. We look for reasons why we can do business, not why we can't. TAGI's strength is derived from our understanding of the market, product quality and high service levels. CDD: What are TAGI's biggest accom- plishments from this prior year? KH: Our biggest accomplishment is the TA G I P harma (C o nt'd. fro m p. 1 ) solidification of long term relationships with some of the largest retailers in the country. We're also very pleased with the launch of Benzonatate Capsules in December 2015. We gained new business partners and signed new development agreements. We watch our Alendronate Sodium Oral Solution as it continues to grow in the marketplace. And on a monthly and annual basis, TAGI Pharma has doubled in sales. CDD: What is TAGI most excited about in the coming year? KH: I'm most excited about the release of our first injectable, part of our long term development strategy. We're all excited to have just launched Metformin ER. Our robust and continuously grow- ing pipeline has more than 14 new prod- ucts expected to launch over the next few years. As TAGI continues to grow, we are very proud to be able to fulfill unmet needs and underserved customers. Visit TAGI Pharma at booth #2322. For more information, go to www.tagi pharma.com or call 855.225.8244. MERIDIAN BIOSCIENCE ACQUIRES MAGELLAN DIAGNOSTICS Meridian Bioscience, Inc., Cincinnati, Ohio, announced that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA- cleared products for the testing of blood to diagnose lead poisoning in children and adults. Today, Magellan is the leading provider of point-of-care lead testing sys- tems with placements in more than 6,500 physician offices and clinics nationwide. Its position in pediatric offices is particu- larly strong. LeadCare ® II, the only CLIA-waived lead testing system, enables physician practices to enhance the quality of care, improve patient com- pliance and convenience, and reduce costs. Magellan's LeadCare Ultra ® and Plus[R] systems are designed for use in hospitals and reference labs. Magellan has a robust product devel- opment pipeline and plans to introduce a third generation platform that will include a menu of additional high value CLIA-waived pediatric tests including, but not limited to lead testing. Magellan's talented team of executives and employ- ees led by Amy Winslow, President and Chief Executive Officer of Magellan, will continue to manage the business, which will remain in its current location and facility. Magellan was acquired from an investor group including Ampersand Capital Partners as the majority owner, along with Abingworth, Tekla Capital Management and Boston Community Venture Fund. Magellan sales for 2015 were $16 million and the business is growing and profitable. Meridian expects Magellan to be accretive to earnings per share during the second half of calendar 2017. Meridian will finance the purchase price of $66 mil- lion using a combination of cash on hand and a $60 million five-year term loan. Meridian remains conservatively capitalized and in a position to maintain its indicated annual cash dividend rate, fund expected growth requirements and pursue additional acquisitions. For more information, visit www .meridianbioscience.com.